Differentiating unirradiated mice from those exposed to conventional or FLASH radiotherapy using MRI
Jeannette JanseniD, Adam KimbleriD, Olivia G.G. DraysoniD, Bernard LanziD, Jessie MossoiD, Veljko GriljiD, Benoît PetitiD, Javier Franco‐PéreziD, Aaron B. SimoniD, Charles L. LimoliiD, Marie‐Catherine VozeniniD, Craig Stark, Paola Ballesteros‐ZebadúaiD
Abstract
Background and purposeThe FLASH effect expands the therapeutic ratio of tumor control to normal tissue toxicity observed after delivery of ultra-high (>100 Gy/s FLASH-RT) vs. conventional dose rate radiation (CONV-RT). In this first exploratory study, we assessed whether ex-vivo Magnetic Resonance Imaging (MRI) could reveal long-term differences after FLASH-RT and CONV-RT whole-brain irradiation. Materials and methodsFemale C57BL/6 mice were divided into three groups: control (non-irradiated), conventional (CONV-RT 0.1 Gy/s), and ultra-high dose rates (FLASH-RT 1 pulse, 5.5 x 106 Gy/s), and received 10 Gy of whole-brain irradiation in a single fraction at 10 weeks of age. Mice were evaluated by Novel Object Recognition cognitive testing at 10 months post-irradiation and were sampled at 13 months post-irradiation. Ex-vivo brains were imaged with a 14.1 Tesla/26 cm magnet with a multimodal MRI protocol, including T2-weighted TurboRare (T2W) and diffusion-weighted imaging (DWI) sequences. ResultsIn accordance with previous results, cognitive tests indicated that animals receiving CONV-RT exhibited a decline in cognitive function, while FLASH-RT performed similarly to the controls. MRI showed decreased hippocampal mean intensity in the CONV-RT mice compared to controls but not in the FLASH-RT group. Comparing CONV-RT to control, we found significant changes in multiple whole-brain diffusion metrics, including the mean Apparent Diffusion Coefficient (ADC) and Mean Apparent Propagator (MAP) metrics. By contrast, no significant diffusion changes were found between the FLASH-RT and control groups. In an exploratory analysis compared to controls, regional diffusion metrics were primarily altered in the basal forebrain and the insular cortex after CONV-RT, and after FLASH-RT, a trend reduction was also observed. ConclusionThis study presents initial evidence that MRI can uncover clear changes in the brain after CONV-RT but not after FLASH-RT. The MRI results aligned with the observed cognitive protection after FLASH-RT, indicating the potential use of MRI to analyze the FLASH response.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A multi-institutional study to investigate the sparing effect after whole brain electron FLASH in mice: Reproducibility and temporal evolution of functional, electrophysiological, and neurogenic endpoints
O. G. G. Drayson, S. Melemenidis, … C. Limoli·bioRxiv·Jan 25, 2024
- Differential and regionally distinct molecular responses distinguish FLASH and conventional RT in a medulloblastoma model while preserving therapeutic outcomes
Michèle Knol, Javier Franco‐Pérez, … Paola Ballesteros‐Zebadúa·bioRxiv·Nov 1, 2026
- Proton FLASH preserves neurocognition across delivery techniques: implications for clinical translation in pediatric brain tumors
Devin Miles, Daniel Sforza, … Sahaja Acharya·bioRxiv·Jun 2, 2026
- Investigating Rat-Brain Normal Tissue and Tumor FLASH Effects with a Novel Very High Energy Electron Beam
Tyler V. Kay, Anna L. Price, … Mark Oldham·bioRxiv·Sep 5, 2025
- Redefining FLASH RT: the impact of mean dose rate and dose per pulse in the gastrointestinal tract
Kevin Liu, Trey Waldrop, … Emil Schüler·International Journal of Radiation Oncology*Biology*PhysicsPeer-reviewed·Apr 23, 2024
- Ultra-High Dose Rate Helium Ion Beams: Minimizing Brain Tissue Damage while Preserving Tumor Control
Ivana Đokić, Mahmoud Moustafa, … Amir Abdollahi·Molecular Cancer TherapeuticsPeer-reviewed·Dec 31, 2024